762 results match your criteria Pruritus and Systemic Disease


Clinicopathological findings and clinical outcomes in 49 cases of feline pemphigus foliaceus examined in Northern California, USA (1987-2017).

Vet Dermatol 2019 Feb 18. Epub 2019 Feb 18.

Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, One Shields Avenue, Davis, CA, 95616, USA.

Background: Few studies have described the pathophysiology, clinical course, treatment outcomes and quality of life (QoL) of cats with pemphigus foliaceus (PF).

Objective: Describe clinicopathological features, treatment outcomes and impacts on QoL in feline PF.

Animals: Forty-nine client-owned cats with PF that presented to a veterinary teaching hospital between 1987 and 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vde.12731DOI Listing
February 2019

Health-related quality of life and costs in Sjögren's syndrome.

Rheumatology (Oxford) 2019 Feb 15. Epub 2019 Feb 15.

National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.

Health-related quality of life (HRQoL) has an increasing role in medical decision-making. This review of the literature aims to provide an overview on HRQoL, costs, and work disability in SS, a disease characterized by focal lymphocytic infiltration of exocrine glands with no therapeutics of proven immunomodulatory potential. HRQoL is markedly reduced in SS in multiple studies across many countries when compared with HRQoL in healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key370DOI Listing
February 2019

Scalp Pruritus: Review of the Pathogenesis, Diagnosis, and Management.

Biomed Res Int 2019 15;2019:1268430. Epub 2019 Jan 15.

Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Scalp pruritus is a frequent problem encountered in dermatological practice. This disorder is caused by various underlying diseases and is a diagnostic and therapeutic challenge. Scalp pruritus may be localized to the scalp or extended to other body areas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/1268430DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350598PMC
January 2019

Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019.

Int Arch Allergy Immunol 2019 Feb 8:1-12. Epub 2019 Feb 8.

Institute of Pharmacology, University of Bern, Bern, Switzerland.

Atopic dermatitis (AD) is a chronic inflammatory skin disease presenting with recurrent eczematous lesions and intense pruritus. It is common and affects both children and adults, often beginning in infancy. Due to the unpredictable disease course, its visible skin lesions, itching and scratching followed by sleeplessness, other associated atopic diseases, and behavioral and psychiatric disorders, AD is an immense burden for patients and caregivers. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/497383
Publisher Site
http://dx.doi.org/10.1159/000497383DOI Listing
February 2019
1 Read

Itch in Psoriasis: A New Look at Well-known Subject.

Acta Derm Venereol 2019 02 8. Epub 2019 Feb 8.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, Poland.

Psoriasis is a chronic inflammatory dermatosis, frequently presenting with chronic itch. This study investigated the prevalence and detailed clinical characteristics of chronic itch in 143 psoriatic patients, with regard to different age groups, comorbidities and pharmacotherapy. Chronic itch was reported by 72% of subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3147DOI Listing
February 2019
2 Reads

Pemphigoid nodularis - rare presentation of bullous pemphigoid: A case report and literature review.

Exp Ther Med 2019 Feb 5;17(2):1132-1138. Epub 2018 Dec 5.

Department of Dermatology, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania.

Pemphigoid nodularis (PN) is a rare clinical variant of bullous pemphigoid characterized by the presence of nodular prurigo-like lesions and pemphigoid blisters. The diagnosis is confirmed by direct immunofluorescence (DIF)/ indirect immunofluorescence (IIF) and immunoserology tests. For some patients, with long mean duration of symptoms, the correct diagnosis of PN is delayed because the disease is not recognized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.7057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327548PMC
February 2019
1 Read

Current and emerging biologic and small molecule therapies for atopic dermatitis.

Expert Opin Biol Ther 2019 Jan 23:1-14. Epub 2019 Jan 23.

a Department of Dermatology, Laboratory of Inflammatory Skin Diseases , Icahn School of Medicine at Mount Sinai , New York , NY , USA.

Introduction: Atopic dermatitis (AD) is the most common inflammatory skin disease, yet until recently there were no safe systemic therapies approved for the long-term management of AD in adult patients. A deeper understanding of disease pathogenesis and identification of molecular and cellular changes has resulted in a rapidly evolving pipeline of therapeutics that holds promise for safer long-term control. Areas covered: In this review, we highlight the growing arsenal of biologic and small molecule antagonists that target pathways implicated in AD pathogenesis. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1573422DOI Listing
January 2019
3 Reads

Current treatment strategies in refractory chronic pruritus.

Curr Opin Pharmacol 2018 Dec 6;46:1-6. Epub 2018 Dec 6.

Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany.

Chronic pruritus is a highly prevalent, debilitating disease, which is often refractory to conventional therapies. A step-wise, guideline-driven approach should be adopted in the management of these patients. Emollients as well as topical corticosteroids if appropriate should be initiated whilst looking for the cause underlying the pruritus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2018.11.007DOI Listing
December 2018
1 Read

Dermatologic manifestations in end stage renal disease.

Hemodial Int 2018 Dec 6. Epub 2018 Dec 6.

Department of Nephrology, Cleveland Clinic Akron General, Akron, Ohio, USA.

Skin manifestations are commonly seen in end stage renal disease (ESRD). Skin involvement in this population can be extensive and dramatically worsen quality of life. Close observation of the skin and nails of ESRD patients by clinicians allows for timely diagnosis and treatment, which ultimately improves quality of life and reduces mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hdi.12689DOI Listing
December 2018
5 Reads

Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients.

Ann Allergy Asthma Immunol 2018 Dec 1. Epub 2018 Dec 1.

The Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York; Department of Dermatology, the Laboratory for Inflammatory Skin Diseases, and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:

Background: Atopic dermatitis (AD) predominantly affects young children, but our understanding of AD pathogenesis is based on skin and blood samples from long-standing adult AD. Genomic biopsy profiling from early pediatric AD showed significant Th2 and Th17/Th22-skewing, without the characteristic adult Th1 up-regulation. Because obtaining pediatric biopsies is difficult, blood gene expression profiling may provide a surrogate for the pediatric skin signature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2018.11.025DOI Listing
December 2018
3 Reads

The Therapeutic Potential of Cannabinoids in Dermatology

Skin Therapy Lett 2018 11;23(6):1-5

Department of Dermatology, The George Washington Medical Faculty Associates, Washington, DC, USA

Cannabinoids have demonstrated utility in the management of cancer, obesity, and neurologic disease. More recently, their immunosuppressive and anti-inflammatory properties have been identified for the treatment of several dermatologic conditions. This review thus assesses the therapeutic potential of phytocannabinoids, endoocannabinoids, and chemically synthetic cannabinoids in the management of cutaneous disease. Read More

View Article

Download full-text PDF

Source
November 2018
4 Reads

Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review.

JAMA Dermatol 2018 Nov 28. Epub 2018 Nov 28.

Department of Dermatology, University of California, Irvine.

Importance: Dermatology is encountering increasing rates of autoimmune disease manifesting in primary skin conditions that are difficult to treat without a risk of immunosuppression. Naltrexone is an orally active opioid antagonist that influences a variety of systemic pathways, including the immune system, in low doses of 1.5 to 4. Read More

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2018.4093DOI Listing
November 2018
17 Reads

Use of antiepileptic mood stabilizers in dermatology.

Clin Dermatol 2018 Nov - Dec;36(6):756-764. Epub 2018 Aug 16.

Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Several antiepileptic drugs (AEDs) are approved by the US Food and Drug Administration for the treatment of bipolar disorder (valproic acid, divalproex, lamotrigine, carbamazepine) and some cutaneous neuropathic pain syndromes (carbamazepine, gabapentin, pregabalin). The AEDs may be effective in the management of (1) chronic pruritus, including pruritus due systemic disease, including uremia, neuropathic pain, neuropathic pruritus, and complex cutaneous sensory syndromes, especially where central nervous system (CNS) sensitization plays a role; (2) management of emotional dysregulation and the resultant repetitive self-excoriation or other cutaneous self-injury in patients who repetitively stimulate or manipulate their integument to regulate emotions (prurigo nodularis, lichen simplex chronicus, skin picking disorder, trichotillomania); (3) management of dermatologic clinical manifestations associated with autonomic nervous system activation (hyperhidrosis, urticaria, flushing; these often occur in conjunction with psychiatric disorders with prominent autonomic activation and dysregulation, eg, social anxiety disorder, posttraumatic stress disorder); and (4) when certain anticonvulsants have a direct therapeutic effect (eg, in psoriasis); currently the use of AEDs for such cases is largely experimental. Gabapentin (dosage range 300-3600 mg daily) is the most widely studied AED mood stabilizer in dermatology and is especially effective in situations where CNS sensitization is a mediating factor. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0738081X183017
Publisher Site
http://dx.doi.org/10.1016/j.clindermatol.2018.08.005DOI Listing
August 2018
16 Reads

Use of maropitant for the control of pruritus in non-flea, non-food-induced feline hypersensitivity dermatitis: an open-label uncontrolled pilot study.

J Feline Med Surg 2018 Nov 14:1098612X18811372. Epub 2018 Nov 14.

3 University of Liège Veterinary Faculty, Small Animal Internal Medicine Service - Dermatology, Liège, Belgium.

Objectives: Non-flea, non-food-induced hypersensitivity dermatitis (NFNFIHD) is a common inflammatory and pruritic skin disease in cats. When avoidance and conventional systemic immunosuppressive treatments fail to control the clinical signs, there are limited treatment options. The aim of this study was to evaluate the efficacy and tolerability of maropitant in feline NFNFIHD. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1098612X18811372
Publisher Site
http://dx.doi.org/10.1177/1098612X18811372DOI Listing
November 2018
12 Reads

Novel drugs for the treatment of chronic pruritus.

Expert Opin Investig Drugs 2018 Dec 19;27(12):981-988. Epub 2018 Nov 19.

a Department of Dermatology and Center for Chronic Pruritus , University Hospital Münster , Münster , Germany.

Introduction: Chronic pruritus (CP) is a multidimensional condition severely affecting the quality of life of those affected. Although a multitude of topical and systemic agents are recommended for CP of different origins, the condition often remains refractory to treatment. However, a deeper understanding of the pathophysiology of CP is leading to the development of novel antipruritic drugs. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13543784.2018.1
Publisher Site
http://dx.doi.org/10.1080/13543784.2018.1548606DOI Listing
December 2018
19 Reads

Generalized rash and pruritus in a 58-year-old woman.

Allergy Asthma Proc 2018 Nov;39(6):468-471

From the Section of Allergy and Immunology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania.

Although allergists often evaluate rashes associated with allergic, IgE mediated etiologies, it is important to consider a wide range of differential diagnoses that includes inflammatory, infectious, and autoimmune etiologies. The case of a 58-year-old woman with a 1-year history of progressive pruritic rash that did not improve with topical creams and steroids is presented. The patient did not state any other symptoms, and a physical examination was notable for a widespread rash. Read More

View Article

Download full-text PDF

Source
http://www.ingentaconnect.com/content/10.2500/aap.2018.39.41
Publisher Site
http://dx.doi.org/10.2500/aap.2018.39.4181DOI Listing
November 2018
8 Reads

Exploratory Study of Intracutaneous Histamine Stimulation in Patient Populations with Chronic Pruritus.

Acta Derm Venereol 2018 11 5. Epub 2018 Nov 5.

vDepartment of Dermatology, University Hospital Muenster, Von-Esmarch-Str. 58, DE-48149 Münster, Germany.

Chronic pruritus can be a diagnostic sign of an underlying disease. In the intracutaneous histamine test, histamine (one of the best-known inducers of pruritus) may cause different reaction patterns depending on the underlying disease. The aim of this study was to determine if an intracutaneous injection of histamine can differentiate between the causes of chronic pruritus and thus be used as a diagnostic test in chronic pruritus of unknown aetiology. Read More

View Article

Download full-text PDF

Source
http://www.medicaljournals.se/acta/content/abstract/10.2340/
Publisher Site
http://dx.doi.org/10.2340/00015555-3078DOI Listing
November 2018
3 Reads

Effects of acupuncture on chronic idiopathic pruritus: an uncontrolled pilot study evaluating inflammatory changes with treatment.

J Complement Integr Med 2018 Nov 3. Epub 2018 Nov 3.

Medical Acupuncture, Ahn Clinic, Scottsdale, AZ, USA.

Background Conduct a pilot study addressing the efficacy of acupuncture in the treatment of chronic idiopathic pruritus to aid in the design of a larger clinical trial. Routine laboratory tests to assess systemic inflammation in addition to subjective patient surveys were performed provide documentation of efficacy of treatment. Methods Patients with chronic pruritus who did not respond to standard treatment were recruited to participate. Read More

View Article

Download full-text PDF

Source
http://www.degruyter.com/view/j/jcim.ahead-of-print/jcim-201
Publisher Site
http://dx.doi.org/10.1515/jcim-2018-0021DOI Listing
November 2018
6 Reads

Itching, chloroquine, and malaria: a review of recent molecular and neuroscience advances and their contribution to mechanistic understanding and therapeutics of chronic non-histaminergic pruritus.

Int J Dermatol 2018 Oct 26. Epub 2018 Oct 26.

Department of Medicine, Division of Clinical Pharmacology, Baylor College of Medicine, Houston, TX, USA.

Chloroquine (CQ) is an antimalarial drug that elicits severe pruritus in black Africans with malaria fever. This acute itching (2-7 days duration) exhibits age dependency and a racial and genetic predilection. CQ itch is non-histaminergic, which makes it both a good model and a tool to probe the mechanisms of chronic itch. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ijd.14252
Publisher Site
http://dx.doi.org/10.1111/ijd.14252DOI Listing
October 2018
19 Reads

Leukotriene receptor antagonists for eczema.

Cochrane Database Syst Rev 2018 10 21;10:CD011224. Epub 2018 Oct 21.

Department of Dermatology, St Helier Hospital, Wrythe Lane, Carshalton, Surrey, UK, SM5 1AA.

Background: Eczema is a common, chronic, inflammatory skin condition that is frequently associated with atopic conditions, including asthma. Leukotriene receptor antagonists (LTRAs) have a corticosteroid-sparing role in asthma, but their role in eczema remains controversial. Currently available topical therapies for eczema are often poorly tolerated, and use of systemic agents is restricted by their adverse effect profile. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/14651858.CD011224.pub2
Publisher Site
http://dx.doi.org/10.1002/14651858.CD011224.pub2DOI Listing
October 2018
10 Reads

Atopic dermatitis.

Allergy Asthma Clin Immunol 2018 12;14(Suppl 2):52. Epub 2018 Sep 12.

2Department of Pediatrics, University of Alberta, Edmonton, AB Canada.

Atopic dermatitis (AD) is a common, chronic skin disorder that can significantly impact the quality of life of affected individuals as well as their families. Although the pathogenesis of the disorder is not completely understood, it appears to result from the complex interplay between defects in skin barrier function, environmental and infectious agents, and immune dysregulation. There are no diagnostic tests for AD; therefore, the diagnosis is based on specific clinical criteria that take into account the patient's history and clinical manifestations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13223-018-0281-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157251PMC
September 2018
2 Reads

Systemic Treatment for Severe Atopic Dermatitis.

Arch Immunol Ther Exp (Warsz) 2018 Aug 22. Epub 2018 Aug 22.

Division of Clinical Immunology and Allergy, University of São Paulo School of Medicine, Artur Ramos 178 ap.211A, Jd. América, São Paulo, SP, CEP: 01454-904, Brazil.

Atopic dermatitis (AD) is a chronic inflammatory, relapsing disease of the skin, characterized by intense pruritus, maculopapular or vesicular erythematous lesions and scaling, sometimes accompanied by oozing, crusts and/or lichenification that has a negative impact on patients' quality of life. Prevalence is higher in children, around 15%, and approximately 5% in adults. Before introducing systemic therapy, it is mandatory to review patients' adherence to the correct use of topical treatments (corticosteroids, calcineurin inhibitors or cresoborole) and/or phototherapy. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00005-018-0521-y
Publisher Site
http://dx.doi.org/10.1007/s00005-018-0521-yDOI Listing
August 2018
10 Reads

Allogeneic adipose-derived mesenchymal stem cell therapy in dogs with refractory atopic dermatitis: clinical efficacy and safety.

Vet Rec 2018 Dec 29;183(21):654. Epub 2018 Aug 29.

Laboratory of Bioengineering and Tissue Regeneration (LABRET), Department of Cell Biology, Genetics and Physiology, Faculty of Sciences, University of Málaga, IBIMA, Málaga, Spain.

Canine atopic dermatitis (AD) is a common skin disease with a 10-15 per cent prevalence. Current treatments vary in their efficacy and safety. The immunomodulatory properties of mesenchymal stem cells (MSCs) make them a promising alternative treatment. Read More

View Article

Download full-text PDF

Source
http://veterinaryrecord.bmj.com/lookup/doi/10.1136/vr.104867
Publisher Site
http://dx.doi.org/10.1136/vr.104867DOI Listing
December 2018
10 Reads

Xerosis cutis and associated co-factors in women with prurigo nodularis.

An Bras Dermatol 2018 Sep-Oct;93(5):671-679

Department of Dermatology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.

Background: Current data regarding the associated factors of prurigo nodularis are still uncertain, except for atopic predisposition.

Objectives: The purposes of this study were to (1) determine the frequencies of xerosis and other accompanying diseases of female patients with prurigo nodularis; (2) compare the demographic, clinical and accompanying disease characteristics by grouping these patients according to whether they have associated xerosis (who were subsequently subgrouped as atopic or non-atopic) or not.

Methods: In this retrospective descriptive study, 80 females with PN were categorized according to the accompanying diseases (dermatological, systemic, neurological, psychogenic, mixed, or undetermined origin). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/abd1806-4841.20187127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106662PMC
October 2018
6 Reads

Itch suppression in mice and dogs by modulation of spinal α2 and α3GABA receptors.

Nat Commun 2018 08 13;9(1):3230. Epub 2018 Aug 13.

Institute of Pharmacology and Toxicology, University of Zürich, Winterthurerstrasse 190, CH-8057, Zürich, Switzerland.

Chronic itch is a highly debilitating condition affecting about 10% of the general population. The relay of itch signals is under tight control by inhibitory circuits of the spinal dorsal horn, which may offer a hitherto unexploited therapeutic opportunity. Here, we found that specific pharmacological targeting of inhibitory α2 and α3GABA receptors reduces acute histaminergic and non-histaminergic itch in mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-05709-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089996PMC
August 2018
8 Reads

Health-related quality of life in patients with cutaneous T-cell lymphoma?

Int J Dermatol 2018 Nov 3;57(11):1314-1319. Epub 2018 Aug 3.

Departments of Dermatology and Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Background: Little is currently known about health-related quality of life (HRQoL) of patients with cutaneous T-cell lymphoma (CTCL), a condition characterized by chronic, pruritic, visible lesions, features which may be uniquely influential.

Objective: The aim of this study was to establish baseline HRQoL data for patients with CTCL and identify its influencing factors.

Methods: Prospective, nonblinded survey design utilizing questionnaires including panels of QoL indices obtained from 105 patients with mycosis fungoides, Sezary syndrome, and CD30+ lymphoproliferative disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14132DOI Listing
November 2018
7 Reads

Neurodystrophic Hand Dermatitis: Sannino Barduagni Syndrome.

Acta Dermatovenerol Croat 2017 Dec;25(4):312-313

lisa Moliterni, MD 2Sapienza University of Rome, Umberto I Polyclinic, Dermatology Department Viale del Policlinico 156 00186 Rome Italy

Hand eczema is a chronic disease (1), commonly considered the expression of a contact allergic or irritative dermatitis. However, when the prick/patch tests and laboratory investigations are negative, important diagnostic challenges may arise. Peripheral nerve fibers are in fact capable of releasing neuromediators. Read More

View Article

Download full-text PDF

Source
December 2017
22 Reads

Less common rheumatologic disorders: Current concepts of skin and systemic manifestations.

Authors:
Taraneh Paravar

Clin Dermatol 2018 Jul - Aug;36(4):525-532. Epub 2018 Apr 10.

Department of Dermatology, University of California-San Diego School of Medicine, San Diego, California, USA. Electronic address:

The cutaneous manifestations of the common rheumatologic disorders, such as systemic lupus erythematosus, dermatomyositis, and systemic sclerosis, are well known. In contrast, the dermatologic findings of less common rheumatologic disorders, including Sjögren syndrome, mixed connective tissue disease, and relapsing polychondritis, are less widely known. The cutaneous manifestations of these connective tissue disorders are reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2018.04.009DOI Listing
December 2018
3 Reads

Systemic sclerosis: Current concepts of skin and systemic manifestations.

Clin Dermatol 2018 Jul - Aug;36(4):459-474. Epub 2018 Apr 12.

Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania, USA; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Systemic sclerosis is an uncommon autoimmune connective tissue disease with multiorgan system involvement and significant associated morbidity and mortality. Cutaneous signs and clinical manifestations are of particular importance, as they may be recognized before systemic manifestations, allowing earlier risk stratification into the limited and diffuse cutaneous subtypes, as well as earlier initiation of treatment. Important cutaneous manifestations include Raynaud's phenomenon, digital ulcers, cutaneous sclerosis, calcinosis cutis, telangiectasias, pruritus, and dyspigmentation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2018.04.004DOI Listing
December 2018
12 Reads

Chronic generalized pruritus without primary skin lesions: a longitudinal prospective observational study.

Int J Dermatol 2019 Mar 24;58(3):273-278. Epub 2018 Jul 24.

Skin Research Center, Department of Dermatology, Razi hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.

Pruritus is among the most common complaints in the field of dermatology. It is also a disturbing symptom of many systemic disorders. Chronic pruritus (CP) refers to the cases of the symptom which last longer than 6 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14125DOI Listing
March 2019
12 Reads

Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis.

Am J Clin Dermatol 2018 Aug;19(4):617-624

Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Dupilumab (Dupixent), a subcutaneously administered, fully human IgG4 monoclonal antibody directed against the IL (interleukin)-4 receptor α subunit, blocks the signalling of IL-4 and IL-13, two T helper cell type 2 cytokines implicated in the immunopathology of atopic dermatitis (AD). It is the first biologic therapy to have been approved for the treatment of adult patients with moderate-to-severe AD in the EU and USA. In phase III trials in adults with moderate-to-severe AD who were inadequately controlled with topical medications and/or systemic treatments, such as ciclosporin, or for whom these therapies were not advisable, 16 weeks' treatment with dupilumab as monotherapy or in combination with topical corticosteroids (TCS) improved multiple measures of disease severity, pruritus, sleep disturbance, anxiety and depression, and quality of life compared with placebo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0370-9DOI Listing
August 2018
6 Reads

A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.

Oncologist 2018 Oct 17;23(10):1119-1126. Epub 2018 Jul 17.

Department of Dermatology, Columbia University Medical Center, New York, New York, USA

Immunotherapy has emerged as a highly effective treatment for numerous cancers. Use of checkpoint inhibitors against various molecules including programmed cell death protein-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 have become widespread in clinical practice. Compared with conventional chemotherapy, immunotherapy is associated with a unique set of immune reactions known collectively as immune-related adverse events (irAEs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0128DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263133PMC
October 2018
33 Reads

Pemphigus herpetiformis in South Tunisia: a clinical expression of pemphigus foliaceus?

Int J Dermatol 2018 Sep 16;57(9):1094-1101. Epub 2018 Jul 16.

Immunology Department, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia.

Background: Pemphigus herpetiformis (PH) is a rare subtype of pemphigus combining clinical features of dermatitis herpetiformis and the immunopathologic characteristics of pemphigus. We aimed to analyze the epidemiological, clinical, and immunological presentation and management of the disease in a cohort of south Tunisian patients with a long-term follow-up.

Methods: We included all patients with confirmed PH followed from January 1987 to December 2015 in the dermatology department. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14139DOI Listing
September 2018
12 Reads

A Case of Allergic Urticaria After Ophthalmic Nepafenac Use.

Turk J Ophthalmol 2018 Jun 28;48(3):146-149. Epub 2018 Jun 28.

Osmangazi University Faculty of Medicine, Department of Ophthalmology, Eskişehir, Turkey.

A 21-year-old male patient with no history of systemic disease or drug use presented to our clinic with redness and pain in the right eye. Best corrected visual acuity was 20/20 in both eyes. Inflamed pinguecula was observed on slit-lamp examination and the patient was prescribed ophthalmic nepafenac eye drops. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4274/tjo.78614DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032958PMC
June 2018
25 Reads

[Systemic lupus erythematosus with marked eosinophilia and clinical features mimicking TAFRO syndrome].

Rinsho Ketsueki 2018 ;59(6):688-694

Department of Hematology, Suita Municipal Hospital.

A 76-year-old woman was referred to our hospital because of fever, hemorrhagic skin lesion with pruritus, and severe thrombocytopenia. Anemia; marked eosinophilia; and elevated ALP, CRP, and soluble IL-2 receptor levels were observed on admission. Both anti-nuclear antibody and Coombs tests were positive. Read More

View Article

Download full-text PDF

Source
https://www.jstage.jst.go.jp/article/rinketsu/59/6/59_688/_a
Publisher Site
http://dx.doi.org/10.11406/rinketsu.59.688DOI Listing
January 2018
9 Reads

Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.

JAMA Dermatol 2018 Aug;154(8):903-912

Regeneron, Tarrytown, New York.

Importance: Real-world data are limited on the patient-reported burden of adult atopic dermatitis (AD).

Objective: To characterize the patient-reported burden of AD with regard to impact of disease severity and inadequate control in adults from clinical settings.

Design, Setting, And Participants: In this cross-sectional study using data from 6 academic medical centers in the United States collected by a self-administered internet-based questionnaire, 1519 adult patients with AD were stratified by AD severity as mild or moderate/severe using the Patient-Oriented Scoring Atopic Dermatitis (PO-SCORAD). Read More

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2018.1572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143024PMC
August 2018
34 Reads

End-Stage Renal Disease Chronic Itch and Its Management.

Dermatol Clin 2018 Jul 26;36(3):277-292. Epub 2018 Apr 26.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Chalubinskiego Street 1, Wrocław 50-368, Poland. Electronic address:

End-stage renal disease chronic itch is a frequent symptom that bothers patients with advanced stages of chronic kidney disease. The pathogenesis of the chronic itch symptom is complex and not yet fully understood and includes many metabolic, immunologic, and neurogenic factors. A significant burden of the disease results in decreased quality of life with sleep impairment, depressive symptoms, and increased mortality of affected individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.det.2018.02.007DOI Listing
July 2018
17 Reads

Pruritus in Autoimmune Connective Tissue Diseases.

Dermatol Clin 2018 Jul 26;36(3):267-275. Epub 2018 Apr 26.

Department of Dermatology, King Khalid University, College of Medicine, PO Box 641, Abha 61421, Saudi Arabia. Electronic address:

Pruritus in autoimmune connective tissue diseases is a common symptom that can be severe and affect the quality of life of patients. It can be related to disease activity and severity or occur independent of the disease. Appropriate therapy to control the itch depends on the etiology, and it is therefore essential to first work-up these patients for the underlying trigger. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.det.2018.02.013DOI Listing
July 2018
1 Read

Chronic Pruritus in the Geriatric Population.

Dermatol Clin 2018 Jul 20;36(3):199-211. Epub 2018 Mar 20.

Department of Dermatology and Cutaneous Surgery, Itch Center Miller School of Medicine, 1295 NW 14th Street, University of Miami Hospital South Building Suites K-M, Miami, FL 33125, USA.

Chronic pruritus (>6 week's duration) in the geriatric population (≥65 years old), is an increasing health care problem. The pathophysiologic predisposing factors are abnormalities of the epidermal barrier, immune system, and nervous system. Causes can be dichotomized into histaminergic and nonhistaminergic pruritus. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07338635183001
Publisher Site
http://dx.doi.org/10.1016/j.det.2018.02.004DOI Listing
July 2018
25 Reads
1.434 Impact Factor

Diagnostic Work-up of the Itchy Patient.

Dermatol Clin 2018 Jul 27;36(3):179-188. Epub 2018 Apr 27.

Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address:

Pruritus is a common and troubling symptom associated with many dermatologic, systemic, neurologic, or psychiatric disorders. This article reviews the current understanding of the pathogenesis of itch and offers a differential diagnosis for the causes of chronic pruritus. The article discusses key diagnostic steps and considerations when evaluating patients with chronic pruritus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.det.2018.02.002DOI Listing
July 2018
1 Read

Possible roles of basophils in chronic itch.

Exp Dermatol 2018 Jun 12. Epub 2018 Jun 12.

Department of Dermatology and Cutaneous Surgery, Miami Itch Center, University of Miami Miller School of Medicine, Miami, FL, USA.

Basophils are blood granulocytes and normally constitute <1% of blood peripheral leucocytes. Basophils share some morphological and functional similarities with mast cells, and basophils were once regarded as redundant and negligible circulating mast cells. However, recent studies reveal the indispensable roles of basophils in various diseases, including allergic and pruritic diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.13705DOI Listing
June 2018
24 Reads

Clinical Characteristics of Pruritus in Systemic Sclerosis Vary According to the Autoimmune Subtype.

Acta Derm Venereol 2018 Aug;98(8):735-741

Department of Dermatology, CHRU Brest, 29609 Brest, France.

Pruritus is a frequent symptom in systemic sclerosis (SSc), with a prevalence of 40-65%, but its pathophysiology is poorly understood. This study investigated the immunological component of pruritus. Fifty-six patients with SSc responded to a standardized questionnaire regarding both SSc disease and pruritus characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-2980DOI Listing
August 2018
9 Reads

Urticarial Lesions in a Pregnant Woman.

Acta Dermatovenerol Croat 2018 Apr;26(1):71-72

Sergio Santos-Alarcon, MD, Department of Dermatology, , Hospital Universitario Doctor Peset, Avinguda Gaspar Aguilar Nº 90, 4601 Valencia, Spain;

Dear Editor, Gestational pemphigoid (GP) is a rare autoimmune bullous dermatosis in pregnancy. GP usually occurs during the second or third month of pregnancy. It clinically manifests as the development of either early-onset urticarial lesions or late-onset subepidermal blisters that may linger for weeks or even months. Read More

View Article

Download full-text PDF

Source
April 2018
7 Reads

Characteristics of Chronic Itch in Systemic Sclerosis: A Cross-sectional Survey.

Acta Derm Venereol 2018 Aug;98(8):793-794

Department of Dermatology, Rush University, Chicago, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-2966DOI Listing
August 2018
9 Reads
3.025 Impact Factor

Treatment of seborrheic dermatitis: a comprehensive review.

J Dermatolog Treat 2018 May 24:1-12. Epub 2018 May 24.

a Department of Dermatology & Cutaneous Surgery , University of Miami Miller School of Medicine , Miami , FL , USA.

Seborrheic dermatitis (SD) is a chronic, recurring inflammatory skin disorder that manifests as erythematous macules or plaques with varying levels of scaling associated with pruritus. The condition typically occurs as an inflammatory response to Malassezia species and tends to occur on seborrheic areas, such as the scalp, face, chest, back, axilla, and groin areas. SD treatment focuses on clearing signs of the disease; ameliorating associated symptoms, such as pruritus; and maintaining remission with long-term therapy. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/09546634.2018.1
Publisher Site
http://dx.doi.org/10.1080/09546634.2018.1473554DOI Listing
May 2018
5 Reads

Ethnic differences and comorbidities of 909 prurigo nodularis patients.

J Am Acad Dermatol 2018 Oct 4;79(4):714-719.e3. Epub 2018 May 4.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Electronic address:

Background: Prurigo nodularis (PN) is a poorly understood, understudied pruritic dermatosis that reduces quality of life.

Objective: To characterize the demographics and comorbidities associated with PN.

Methods: Cross-sectional study of patients 18 years and older who were seen at the Johns Hopkins Health System between December 6, 2012, and December 6, 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.04.047DOI Listing
October 2018
7 Reads

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.

J Eur Acad Dermatol Venereol 2018 May;32(5):657-682

Christine Kühne Center for Allergy Research and Education CK-CARE, Davos, Switzerland.

This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic reviews and published studies into account. This first part of the guideline covers methods, patient perspective, general measures and avoidance strategies, basic emollient treatment and bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy, whereas the second part covers antimicrobial therapy, systemic treatment, allergen-specific immunotherapy, complementary medicine, psychosomatic counselling and educational interventions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.14891DOI Listing
May 2018
14 Reads

Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.

J Dermatol 2018 Jun 17;45(6):701-709. Epub 2018 Apr 17.

Clinical Development Department, Pharmaceutical Division, Japan Tobacco Inc., Tokyo, Japan.

The purpose of the present two phase 1 studies was to assess the safety, tolerability and pharmacokinetics for topical application of a novel Janus kinase (JAK) inhibitor, JTE-052, in Japanese healthy adult male volunteers and Japanese adult patients with atopic dermatitis (AD). Additionally, exploratory investigation was performed on the efficacy for disease severity and pruritus score in AD patients. In the QBX1-1 study, the cutaneous safety of JTE-052 ointment by a patch test and a photo patch test was assessed in an intra-individual comparative study using placebo ointment, white petrolatum and non-application as comparators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001687PMC
June 2018
4 Reads
2.350 Impact Factor

Lymphocytic Mural Folliculitis Resembling Epitheliotropic Lymphoma in Tigers ( Panthera tigris).

Vet Pathol 2018 09 16;55(5):731-735. Epub 2018 Apr 16.

2 Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA.

A striking form of lymphocytic mural folliculitis is described in 6 tigers ( Panthera tigris). Clinically, all tigers exhibited regionally extensive chronic, variably waxing and waning alopecia with minimal scaling and crusting most pronounced over the head, neck, and shoulders. More severely affected tigers exhibited marked hyperpigmentation and lichenification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300985818766213DOI Listing
September 2018
9 Reads